Format

Send to

Choose Destination
J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):188-192. doi: 10.1097/QAI.0000000000001487.

Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa?

Author information

1
*BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada; †Department of Infectious Diseases, Massachusetts General Hospital, Boston, MA; ‡Harvard University Center for AIDS Research, Harvard Medical School, Boston, MA; §Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda; ‖HIV/AIDS division, University of California, San Francisco, CA; ¶Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA; #School of Public Health, Oregon Health Sciences University, Portland, OR; and **Center for Cancer Research, National Cancer Institute, Frederick, MD.

Abstract

Despite a poor toxicity profile, zidovudine supersedes abacavir (ABC) as an alternative first-line agent in most international treatment guidelines because of concerns about HLA-B*57:01-related ABC-hypersensitivity. We detected one case of HLA-B*57:01 carriage among 513 HIV-infected individuals in Uganda, which, in combination with previous reports, supports the safety of ABC in the region.

PMID:
28639996
PMCID:
PMC5597467
DOI:
10.1097/QAI.0000000000001487
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center